Borja-Flores Adrián, Macías-Hernández Salvador I, Hernández-Molina Gabriela, Perez-Ortiz Andric, Reyes-Martínez Eloy, Belzazar-Castillo de la Torre José, Ávila-Jiménez Laura, Vázquez-Bello María Cristina, León-Mazón Marco Antonio, Furuzawa-Carballeda Janette, Torres-Villalobos Gonzalo, Romero-Hernández Fernanda, Albavera-Hernández Cidronio, Pérez-Correa Jesús, Castro-Rocha Hilda A
HGZ 5 Con MF, Delegación Estatal Morelos, Zacatepec, Morelos, Mexico.
Orthopedic Rehabilitation Division, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra, Mexico City, Mexico.
Adv Orthop. 2020 Jul 22;2020:9398274. doi: 10.1155/2020/9398274. eCollection 2020.
Polymerized-type I collagen (polymerized-collagen) is a downregulator of inflammation and a tissue regenerator. The aim was to evaluate the effect of intra-articular injections (IAIs) of polymerized-collagen among patients with symptomatic knee osteoarthritis (OA) in delaying or preventing joint replacement surgery. . This was a cohort study of 309 patients with knee OA. Patients with mild-to-moderate disease were treated weekly with IAIs of 2 mL of polymerized-collagen for six weeks ( = 309). Follow-up was for 6-60 months. The primary endpoints included the following determinations: (1) therapeutic effect; (2) survival from total knee replacement surgery (TKR); (3) Western Ontario and McMaster University Osteoarthritis Index (WOMAC) and pain (visual analogue scale, VAS). Clinical improvement was defined as a decrease in pain exceeding 20 mm on the VAS and the achievement of at least 20% improvement from baseline with respect to the WOMAC score. Radiographic analysis was performed at baseline and 60 months. The joint space width in the medial, lateral, and patellofemoral compartments was calculated.
Patients who received IAIs of polymerized-collagen had a statistically significant improvement in the primary criteria ( < 0.05). Kaplan-Meier survival analysis of the therapeutic effect demonstrated 98.8% survival at 60 months with TKR as the endpoint. There was no significant reduction in joint space in any compartment based on the analyzed radiographs. No serious adverse events were recorded.
Polymerized-collagen increased the time to TKR by at least 60 months, modifying the disease course, improving functional disability, and decreasing pain.
聚合I型胶原蛋白(聚合胶原蛋白)是一种炎症下调因子和组织再生剂。本研究旨在评估症状性膝关节骨关节炎(OA)患者关节腔内注射(IAIs)聚合胶原蛋白在延迟或预防关节置换手术方面的效果。这是一项针对309例膝关节OA患者的队列研究。中轻度疾病患者每周接受2毫升聚合胶原蛋白的关节腔内注射,共六周(n = 309)。随访6至60个月。主要终点包括以下测定:(1)治疗效果;(2)全膝关节置换术(TKR)的生存情况;(3)西安大略和麦克马斯特大学骨关节炎指数(WOMAC)及疼痛(视觉模拟量表,VAS)。临床改善定义为VAS疼痛评分下降超过20毫米,且WOMAC评分较基线至少改善20%。在基线和60个月时进行影像学分析。计算内侧、外侧和髌股关节间隙宽度。
接受聚合胶原蛋白关节腔内注射的患者在主要标准方面有统计学意义的改善(P < 0.05)。以TKR为终点的治疗效果的Kaplan-Meier生存分析显示,60个月时生存率为98.8%。根据分析的X线片,任何关节间隙均无明显减小。未记录到严重不良事件。
聚合胶原蛋白使TKR时间增加至少60个月,改变了疾病进程,改善了功能残疾,并减轻了疼痛。